HIMS
Hims & Hers Health, Inc.
There isn't enough reported data to score HIMS yet.
OM
Outset Medical, Inc.
There isn't enough reported data to score OM yet.
HIMS Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Stable | |
| Strong |
HIMS's revenue and balance sheet are currently strong, and its cash flow is stable, but its profitability is weak.
OM Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Weak | |
| Under pressure | |
| Unavailable |
OM's revenue is currently healthy, but its profitability and cash flow are under pressure. There isn't enough data to rate its balance sheet.
HIMS PE Valuation
HIMS has no meaningful PE right now: it lost money over the past year.
OM PE Valuation
OM has no meaningful PE right now: it lost money over the past year.
HIMS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Turning to a loss | |
| Strong growth | |
| Stable | |
| Limited | |
| Low |
Analysts expect HIMS's revenue to grow, but its earnings to decline. However, they disagree widely on these estimates.
OM Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Growth | |
| Strongly improving | |
| Limited | |
| Low |
OM has the edge over HIMS on the outlook, with more favorable earnings and profitability expectations.
HIMS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.83 | -257% |
| Q2 2026 | -$0.63 | -180% |
| Q1 2026 | -$0.09 | -113% |
| Q4 2025 | $0.51 | -3.8% |
| Q3 2025 | $0.53 | +20% |
| Q2 2025 | $0.79 | +888% |
| Q1 2025 | $0.68 | +$0.69 |
| Q4 2024 | $0.53 | +$0.64 |
HIMS has swung to a loss: it lost $0.83 per share over the past year, after a profit the year before.
OM Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2022 | -$51.45 | -$10.05 |
| Q2 2022 | -$48.45 | +$34.80 |
OM has the edge over HIMS in the latest year-over-year earnings comparison.
HIMS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $890.4M | +49% |
| Q2 2026 | $753.2M | +38% |
| Q1 2026 | $608.1M | +3.8% |
| Q4 2025 | $617.8M | +28% |
| Q3 2025 | $599M | +49% |
| Q2 2025 | $544.8M | +73% |
| Q1 2025 | $586M | +111% |
| Q4 2024 | $481.1M | +95% |
HIMS has the edge over OM on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -7.4% | -9.4 points |
| Q2 2026 | -13% | -18 points |
| Q1 2026 | -13% | -23 points |
| Q4 2025 | 1.5% | -2.4 points |
| Q3 2025 | 2% | -3.6 points |
| Q2 2025 | 4.9% | +1.4 points |
| Q1 2025 | 9.9% | +6.3 points |
| Q4 2024 | 3.9% | +4 points |
HIMS has the edge over OM on profitability, with a higher operating margin.
OM Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $33.6M | +14% |
| Q2 2026 | $31.6M | +0.7% |
| Q1 2026 | $27.9M | -6.3% |
| Q4 2025 | $28.9M | -2% |
| Q3 2025 | $29.4M | +2.7% |
| Q2 2025 | $31.4M | +15% |
| Q1 2025 | $29.8M | +5.6% |
| Q4 2024 | $29.5M | -3.4% |
OM's revenue grew through 2023 and has held roughly level since: $34M last quarter, up 14% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -37% | +17 points |
| Q2 2026 | -50% | +4.1 points |
| Q1 2026 | -61% | -5.6 points |
| Q4 2025 | -61% | +13 points |
| Q3 2025 | -54% | +29 points |
| Q2 2025 | -54% | +59 points |
| Q1 2025 | -55% | +76 points |
| Q4 2024 | -74% | +48 points |
OM's operating margin was −37% last quarter, up 17 points from the same quarter a year ago, near the top of its range since 2019.
HIMS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $26M | -67% |
| Q2 2026 | -$68.2M | +$1.3M |
| Q1 2026 | $53.1M | +5.9% |
| Q3 2025 | $79.3M | -7% |
| Q2 2025 | -$69.5M | -230% |
| Q1 2025 | $50.1M | +94% |
| Q3 2024 | $85.3M | +238% |
| Q2 2024 | $53.6M | +219% |
HIMS has the edge over OM on cash generation, producing positive trailing cash flow while its opponent burns cash.
OM Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$10.5M | -$4M |
| Q2 2026 | -$9.7M | -$4.6M |
| Q1 2026 | -$12.9M | +$12.9M |
| Q4 2025 | -$9.7M | +$6.8M |
| Q3 2025 | -$6.5M | +$14.5M |
| Q2 2025 | -$5.1M | +$28.3M |
| Q1 2025 | -$25.8M | +$20.5M |
| Q4 2024 | -$16.5M | +$9M |
OM has burned cash in almost every quarter: −$43M over the past year, against −$54M the year before.
HIMS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.9% | +2.1M shares |
| 1 year | -6% | -14.9M shares |
| 3 years | +11% | +23.7M shares |
| 5 years | +17% | +33.8M shares |
HIMS has the edge over OM on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2025 | $80.5M |
| Q3 2025 | $9.5M |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | $5M |
| Q3 2024 | $30M |
| Q2 2024 | $19.9M |
| Q1 2024 | $28.1M |
OM Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -2.1% | -66.6K shares |
| 1 year | +271% | +2.2M shares |
OM has 3M diluted shares, up 271% from a year ago.
| Quarter | Spent |
|---|---|
| Q2 2020 | — |
| Q1 2020 | — |
| Q4 2019 | — |
HIMS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | -5.9x | Net Cash |
| Q4 2025 | -1.4x | Net Cash |
| Q3 2025 | -2.2x | Net Cash |
| Q2 2025 | -7.3x | Net Cash |
| Q1 2025 | -2.1x | Net Cash |
| Q4 2024 | -2.8x | Net Cash |
| Q3 2024 | -2.9x | Net Cash |
| Q2 2024 | -5.5x | Net Cash |
HIMS has more cash than debt.
OM Net Leverage
OM's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
HIMS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.0 | Neutral |
| Stochastic | 23.0 | Neutral |
HIMS's weekly RSI is 36 (neutral) and its Stochastic is 23 (neutral).
OM Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 45.3 | Neutral |
| Stochastic | 49.2 | Neutral |
OM's weekly RSI is 45 (neutral) and its Stochastic is 49 (neutral).
HIMS PE vs Healthcare Sector
| Metric | HIMS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
HIMS has no meaningful PE right now: it lost money over the past year.
OM PE vs Healthcare Sector
OM has no meaningful PE right now: it lost money over the past year.
HIMS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $27.3 | 28% below |
| 20 week MA | $29.2 | 32% below |
| 50 week MA | $27.7 | 29% below |
| 100 week MA | $35.9 | 45% below |
| 200 week MA | $24.4 | 19% below |
HIMS is in a downtrend: it's below all five of its weekly moving averages, and 19% below its 200-week average.
OM Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $3.90 | 1% below |
| 20 week MA | $4.03 | 4.2% below |
| 50 week MA | $4.10 | 5.9% below |
| 100 week MA | $9.02 | 57% below |
| 200 week MA | $73.2 | 95% below |
OM is in a downtrend: it's below all five of its weekly moving averages, and 95% below its 200-week average.
HIMS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.89 | $15.0 | +51% |
| 2021 | $15.0 | $6.65 | -56% |
| 2022 | $6.65 | $6.43 | -3.3% |
| 2023 | $6.43 | $8.90 | +38% |
| 2024 | $8.90 | $26.6 | +198% |
| 2025 | $26.6 | $34.3 | +29% |
| 2026 YTD | $34.3 | $19.7 | -42% |
HIMS's yearly returns have swung widely, from +198% in 2024 to −56% in 2021. It's down 42% so far in 2026.
OM Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $900.2 | $798.9 | -11% |
| 2021 | $798.9 | $681.2 | -15% |
| 2022 | $681.2 | $378.8 | -44% |
| 2023 | $378.8 | $81.2 | -79% |
| 2024 | $81.2 | $17.1 | -79% |
| 2025 | $17.1 | $3.36 | -80% |
| 2026 YTD | $3.36 | $3.86 | +15% |
OM has the edge over HIMS on returns for 2026, with the stronger performance.